Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01336842 · ClinicalTrials.gov registry record · Phase 1
Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors
A Phase 1 study of Solid Tumors and Non-small Cell Lung Cancer (NSCLC), sponsored by University of California, Davis.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
- 2
- Study locations
NCT01336842: Completed Phase 1 study of Solid Tumors and Non-small Cell Lung Cancer (NSCLC), sponsored by University of California, Davis.
NCT01336842 is a Phase 1 study of Solid Tumors and Non-small Cell Lung Cancer (NSCLC) that has completed, run by University of California, Davis. The registered enrollment target is 23 participants, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (92% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01336842, a Phase 1 study of Solid Tumors and Non-small Cell Lung Cancer (NSCLC), has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to find out if panobinostat taken with cisplatin and pemetrexed can be used safely without increasing side effects and that the combination will have a better effect than platinum-based doublet chemotherapy alone.
Primary Outcome
Safety assessments will consist of monitoring and recording all adverse events and serious adverse events, the regular monitoring of hematology, blood chemistry and urine values, regular measurement of vital signs and the performance of physical examination. Safety and tolerability will be assessed according to the NCI CTCAE v4.
Conditions Studied
Interventions
- DRUG Panobinostat, Cisplatin, Pemetrexed
Study Locations (2)
California
- University of California Davis Cancer Center - Sacramento
Michigan
- Henry Ford Health System - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2011-04 |
| Est. Completion | 2017-06 |
| Phase | Phase 1 |
What the finished NCT01336842 record still lists
NCT01336842 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (92% lower).
The record links to 2 conditions, with Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which Panobinostat, Cisplatin, Pemetrexed is the first listed.
NCT01336842 reports a single indexed study location in California, Michigan.
Frequently Asked Questions
What is clinical trial NCT01336842 about?
NCT01336842 is a clinical study titled "Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors". The purpose of this study is to find out if panobinostat taken with cisplatin and pemetrexed can be used safely without increasing side effects and that the combination will have a better effect than platinum-based doublet chemotherapy alone.
What is the current status of trial NCT01336842?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2011-04. Estimated completion is 2017-06.
What conditions does trial NCT01336842 study?
This clinical trial studies the following conditions: Solid Tumors, Non-small Cell Lung Cancer (NSCLC).
What interventions are being tested in trial NCT01336842?
The interventions under investigation include: Panobinostat, Cisplatin, Pemetrexed (DRUG).
Who is sponsoring clinical trial NCT01336842?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01336842 being conducted?
This trial has 2 study locations across California, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01336842's enrollment target sits among peer trials
23 113th of 125 higher than 13 of 125 other Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of INCB123667 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
RECRUITING · Phase 1
-
Study of AUBE00 in Patients With Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia